Rosen, top-ranked investor counsel, encourages zenas biopharma, inc. investors to secure counsel before important deadline in securities class action first filed by the firm - zbio

New york city, ny / access newswire / may 11, 2025 / why: rosen law firm, a global investor rights law firm, reminds purchasers of the securities of zenas biopharma, inc.(nasdaq: zbio) pursuant and/or traceable to the registration statement and prospectus (collectively, the "registration statement") issued in connection with zenas biopharma's september 2024 initial public offering ("ipo" or the "offering"), of the important june 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm. so what: if you purchased zenas biopharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
TOP Ratings Summary
TOP Quant Ranking